Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 25 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia AreataCompletedNCT03941548Phase 2Results posted
• A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)CompletedNCT03940703Phase 2Results posted
• Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell CarcinomaActive, not recruitingNCT03937219Phase 3Results posted
• Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative ColitisCompletedNCT03934216Phase 2Results posted
• Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell MalignanciesActive, not recruitingNCT03932331Phase 1/2Results posted
• A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult ParticipantsCompletedNCT03928327Phase 1Results posted
• This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistaminesCompletedNCT03926611Phase 2Results posted
• Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial SpondyloarthritisCompletedNCT03926195Phase 2Results posted
• An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe PsoriasisCompletedNCT03924427Phase 3Results posted
• Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMMLTerminatedNCT03922100Phase 1/2Results posted
• JAK Inhibitor Treatment in AGSCompletedNCT03921554Phase 2Results posted
• Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus ErythematosusCompletedNCT03920267Phase 2Results posted
• TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) StudyTerminatedNCT03920254Phase 2/3Results posted
• A Study of Baricitinib (LY3009104) in Participants With Rheumatoid ArthritisCompletedNCT03915964Phase 4Results posted
• Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic DermatitisCompletedNCT03915496Phase 2Results posted
• Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid CancerActive, not recruitingNCT03914300Phase 2Results posted
• A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in ChinaCompletedNCT03909971Phase 2Results posted
• Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung CancerTerminatedNCT03906071Phase 3Results posted
• Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic DermatitisCompletedNCT03903822Phase 2Results posted
• Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy VolunteersCompletedNCT03901313Phase 1Results posted
• A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsActive, not recruitingNCT03899792Phase 1/2Results posted
• A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia AreataCompletedNCT03899259Phase 3Results posted
• Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)CompletedNCT03898180Phase 3Results posted
• A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque PsoriasisCompletedNCT03895372Phase 2Results posted
• A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and RifabutinCompletedNCT03891901Phase 2Results posted
• A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been CompletedCompletedNCT03890731Phase 2Results posted
• Dose-finding Study for SAR442168 in Relapsing Multiple SclerosisCompletedNCT03889639Phase 2Results posted
• Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy BodiesCompletedNCT03888222Phase 2Results posted
• Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)CompletedNCT03884101Phase 3Results posted
• Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)CompletedNCT03881059Phase 2Results posted
• Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative NeoplasmsTerminatedNCT03878199Phase 1/2Results posted
• A Study of Copanlisib and Ibrutinib in Mantle Cell LymphomaCompletedNCT03877055Phase 1/2Results posted
• A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic LeukemiaCompletedNCT03873493Phase 2Results posted
• A Study in Healthy Men to Test Whether Food Affects the Amount of BI 894416 in the BloodCompletedNCT03871595Phase 1Results posted
• Evaluate Severe Hepatic Impairment on Dacomitinib PKCompletedNCT03865446Phase 1Results posted
• Osimertinib Study in Indian PatientsCompletedNCT03853551Phase 4Results posted
• Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In PsoriasisCompletedNCT03850483Phase 2Results posted
• A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in PatientsStatus unknownNCT03849768Phase 3Results posted
• Itacitinib for Low Risk GVHDCompletedNCT03846479Phase 2Results posted
• Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone LymphomaCompletedNCT03846427Phase 2Results posted
• A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)CompletedNCT03845517Phase 2Results posted
• A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)TerminatedNCT03843125Phase 3Results posted
• Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid LeukemiaCompletedNCT03836209Phase 2Results posted
• Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute LeukemiaActive, not recruitingNCT03834961Phase 2Results posted
• Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)TerminatedNCT03834220Phase 2Results posted
• Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung CancerActive, not recruitingNCT03831932Phase 1/2Results posted
• Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)CompletedNCT03829332Phase 3Results posted
• Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)CompletedNCT03829319Phase 3Results posted
• Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal CancerCompletedNCT03828799Phase 1/2Results posted
• Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis SuppurativaCompletedNCT03827798Phase 2Results posted
• A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With UpadacitinibTerminatedNCT03823378Phase 2Results posted
• Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)TerminatedNCT03822117Phase 2Results posted
• Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)CompletedNCT03820986Phase 3Results posted
• A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)CompletedNCT03820726Phase 3Results posted
• Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia AreataCompletedNCT03811912Phase 2Results posted
• A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy ParticipantsCompletedNCT03811834Phase 1Results posted
• A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung CancerActive, not recruitingNCT03807778Phase 1Results posted
• Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene FusionsTerminatedNCT03805841Phase 2Results posted
• Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia AreataCompletedNCT03800979Phase 4Results posted
• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)CompletedNCT03797326Phase 2Results posted
• JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic DermatitisCompletedNCT03796676Phase 3Results posted
• Study of PF 04965842 Effect on MATE1/2K Activity in Healthy ParticipantsCompletedNCT03796182Phase 1Results posted
• Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent SarcoidosisCompletedNCT03793439Phase 1Results posted
• Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic LymphomaCompletedNCT03788291Phase 2Results posted
• An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With LymphomaTerminatedNCT03779113Phase 1Results posted
• Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior OsimertinibActive, not recruitingNCT03778229Phase 2Results posted
• Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)CompletedNCT03776136Phase 2Results posted
• Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell TransplantCompletedNCT03774082Phase 2Results posted
• A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic ArthritisCompletedNCT03773978Phase 3Results posted
• Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/TranslocationsTerminatedNCT03773302Phase 3Results posted
• LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple MyelomaCompletedNCT03773107Phase 1/2Results posted
• A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHACompletedNCT03764618Phase 3Results posted
• A Study of PRN1008 in Patients With PemphigusTerminatedNCT03762265Phase 3Results posted
• ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)TerminatedNCT03759340Phase 2Results posted
• Efficacy & Safety of TD-1473 in Ulcerative ColitisTerminatedNCT03758443Phase 2/3Results posted
• Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer TherapyActive, not recruitingNCT03755791Phase 3Results posted
• A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibTerminatedNCT03755518Phase 3Results posted
• Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell TransplantationCompletedNCT03755414Phase 1Results posted
• TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic DermatitisCompletedNCT03745651Phase 3Results posted
• Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic DermatitisCompletedNCT03745638Phase 3Results posted
• A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to PoziotinibTerminatedNCT03744715Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCATerminatedNCT03742973Phase 2Results posted
• Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell LymphomaCompletedNCT03742258Phase 1Results posted
• A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT03738397Phase 3Results posted
• Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerTerminatedNCT03737994Phase 2Results posted
• Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid LeukemiaTerminatedNCT03735875Phase 1/2Results posted
• A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic LeukemiaCompletedNCT03734016Phase 3Results posted
• A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic DermatitisCompletedNCT03733301Phase 3Results posted
• PF-06651600 for the Treatment of Alopecia AreataCompletedNCT03732807Phase 2/3Results posted
• A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)CompletedNCT03730012Phase 1/2Results posted
• Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand EczemaCompletedNCT03728504Phase 2Results posted
• Hepatic Impairment Study for Lorlatinib in Cancer PatientsTerminatedNCT03726333Phase 1Results posted
• Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.CompletedNCT03725722Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell ArteritisCompletedNCT03725202Phase 3Results posted
• Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 ExpansionActive, not recruitingNCT03722407Phase 2Results posted
• A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 894416 in the BloodCompletedNCT03722173Phase 1Results posted
• Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric SubjectsTerminatedNCT03721965Phase 1/2Results posted
• Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical TherapyCompletedNCT03720470Phase 3Results posted
• A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid TumorsTerminatedNCT03717415Phase 1/2Results posted
• A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo SubjectsCompletedNCT03715829Phase 2Results posted

← Tyrosine Kinase Inhibitors overview